AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avita Therapeutics

1.680

-0.020-1.18%

Volume:247.89K

Turnover:415.60K

Market Cap:223.09M

PE:-0.06

High:1.705

Open:1.680

Low:1.640

Close:1.700

Loading ...

Overview Company News Filings

Ask the analyst: Can ASX growth story turn a profit before it’s too late?

Morning Star AU

Stock Track | Avita Therapeutics Soars 5.26% as Study Shows Recell System Reduces Hospital Stays for Burn Patients

Stock Track | Avita Therapeutics Soars 5.26% as Study Shows Recell System Reduces Hospital Stays for Burn Patients

Avita Medical Says Data Show Recell Reduced Length of Hospital Stay for Burn Patients

MT Newswires Live

Avita Medical Says Dermal Matrix Shows 'Significantly' Faster Wound Bed Vascularization, Autograft Readiness

MT Newswires Live

ASX Biggest Losers

MT Newswires Live

Stock Track | Avita Therapeutics Plummets 20.74% as Q1 Earnings Miss Analyst Expectations

Avita Medical's Loss Narrows in Q1 as Revenue Grows; Shares Down 20%

MT Newswires Live

AVITA Medical to Host Acute Wound Care Showcase on May 13, 2025

AVITA Medical to Announce First Quarter 2025 Financial Results

Stock Track | Avita Therapeutics Soars 11.20% on Breakthrough Clinical Data Presentation at ABA 2025

AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025

Avita Medical's Cohealyx Wound Treatment Makes Commercial Launch in US; Shares Down 4%

MT Newswires Live

Guess which ASX All Ords stock just leapt 9% on big US news

AVITA Secures Manufacturing, Amends Distribution Agreement with US-Based Healthcare Tech Provider; Shares Rise 7%

MT Newswires Live

Does Avita Medical (RCEL) Have the Potential to Rally 73.72% as Wall Street Analysts Expect?

AVITA Medical Full Year 2024 Earnings: Misses Expectations

Simply Wall St.

AVITA Medical to Host Investor Webinar Briefing

Avita Medical Reports Wider Q4 Loss Despite Higher Revenue; Shares Up 12%

MT Newswires Live

AVITA Medical, Inc. (RCEL): A Bull Case Theory

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AVH.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVH.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVH.AU\",,,,,undefined,":{"symbol":"AVH.AU","market":"AU","secType":"STK","nameCN":"Avita Therapeutics","latestPrice":1.68,"timestamp":1752732660373,"preClose":1.7,"halted":0,"volume":247892,"delay":0,"nameEN":"Avita Therapeutics","floatShares":3243354,"shares":132792390,"eps":-27.02430044296157,"marketStatus":"Post Close","change":-0.02,"latestTime":"07-17 16:18:25 AEST","open":1.68,"high":1.705,"low":1.64,"amount":415603,"amplitude":0.038235,"askPrice":1.68,"askSize":36289,"bidPrice":1.675,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-27.02430044296157,"tradingStatus":3,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1752796800000},"marketStatusCode":15,"adr":0,"adrRate":8,"exchange":"ASX","adjPreClose":1.7,"openAndCloseTimeList":[[1752710400000,1752732000000]],"volumeRatio":0.949377,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVH.AU\",,,,,undefined,":{"symbol":"AVH.AU","floatShares":3243354,"roa":"-38.35%","roe":"-407.50%","lyrEps":-29.471989,"volumeRatio":0.949377,"shares":132792390,"dividePrice":0,"high":1.705,"amplitude":0.038235,"preClose":1.7,"low":1.64,"week52Low":1.48,"pbRate":"-31.65","psRate":"2.02","week52High":4.52,"institutionHeld":0,"latestPrice":1.68,"committee":-0.847285,"eps":-27.02430044296157,"divideRate":0,"volume":247892,"delay":0,"ttmEps":-27.02430044296157,"open":1.68,"prevYearClose":4.25,"prevWeekClose":1.805,"prevMonthClose":1.715,"prevQuarterClose":1.715,"fiveDayClose":1.775,"twentyDayClose":1.575,"sixtyDayClose":2.9},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVH.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548827817","title":"Ask the analyst: Can ASX growth story turn a profit before it’s too late?","url":"https://stock-news.laohu8.com/highlight/detail?id=2548827817","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548827817?lang=en_us&edition=fundamental","pubTime":"2025-07-02 00:00","pubTimestamp":1751385600,"startTime":"0","endTime":"0","summary":"Welcome to the next edition of Ask the analyst, where I put questions from Morningstar readers (and a few of my own) to our equity research team. If you have a question about an ASX share or industry ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/stocks/ask-analyst-can-asx-growth-story-turn-profit-before-its-too-late","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["BK7508","BK7067","AVH.AU"],"gpt_icon":0},{"id":"1125134097","title":"Stock Track | Avita Therapeutics Soars 5.26% as Study Shows Recell System Reduces Hospital Stays for Burn Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1125134097","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125134097?lang=en_us&edition=fundamental","pubTime":"2025-06-10 08:14","pubTimestamp":1749514479,"startTime":"0","endTime":"0","summary":"Avita Therapeutics  saw its stock soar 5.26% in Tuesday's trading session following the release of promising data for its Recell system. The surge came after researchers presented findings at the annual meeting of the British Burn Association, demonstrating significant benefits for burn patients treated with the company's innovative technology.The positive results from this large-scale study could potentially boost the adoption of Avita's Recell system in burn treatment centers worldwide. As hea","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AVH.AU"],"gpt_icon":0},{"id":"1109280284","title":"Stock Track | Avita Therapeutics Soars 5.26% as Study Shows Recell System Reduces Hospital Stays for Burn Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1109280284","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109280284?lang=en_us&edition=fundamental","pubTime":"2025-06-10 08:14","pubTimestamp":1749514460,"startTime":"0","endTime":"0","summary":"Avita Therapeutics  saw its stock price surge 5.26% in Tuesday's trading session following the release of positive data for its Recell system. The company announced that researchers presented compelling evidence at the annual meeting of the British Burn Association, demonstrating significant benefits for burn patients treated with the Recell system.These findings underscore the potential of Avita's Recell system to revolutionize burn treatment, offering substantial benefits to both patients and ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Avita Therapeutics Soars 5.26% as Study Shows Recell System Reduces Hospital Stays for Burn Patients","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AVH.AU"],"gpt_icon":0},{"id":"2542199356","title":"Avita Medical Says Data Show Recell Reduced Length of Hospital Stay for Burn Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2542199356","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542199356?lang=en_us&edition=fundamental","pubTime":"2025-06-10 08:02","pubTimestamp":1749513772,"startTime":"0","endTime":"0","summary":"Avita Medical  said researchers presented data at the annual meeting of the British Burn Association demonstrating reduced length of hospital stays among burn patients treated with the Recell system, according to a Tuesday Australian bourse filing.The study, representing the largest real-world analysis of skin cell suspension autograft, or Recell, analyzed registry data from over 6,300 patients treated with Recell between 2019 and 2024.For patients with burns covering less than 30% total body surface area, their hospital stay was reduced by 6.2 days or about 36% if they were treated with Recell Spray-On Skin Cells alone, compared with patients treated with split-thickness autografts.The reduced lengths of stay led to cost savings of around AU$300 million over the five-year study period.The session was titled \"The Clinical Impact of Skin Cell Suspension Autograft from a National Registry Perspective,\" and the study was presented by Jeffrey Carter of Louisiana State University Health and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","AVH.AU","BK7508"],"gpt_icon":0},{"id":"2541500142","title":"Avita Medical Says Dermal Matrix Shows 'Significantly' Faster Wound Bed Vascularization, Autograft Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2541500142","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541500142?lang=en_us&edition=fundamental","pubTime":"2025-06-06 06:47","pubTimestamp":1749163648,"startTime":"0","endTime":"0","summary":"Avita Medical (ASX:AVH) published clinical results that showed two patients with complex full-thickness hand wounds treated with its collagen-based dermal matrix, Cohealyx, achieved autograft readines","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVH.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2534819114","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2534819114","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534819114?lang=en_us&edition=fundamental","pubTime":"2025-05-09 10:43","pubTimestamp":1746758590,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest losses on Friday.Saferoads Holdings : -33%, AU$0.18MedAdvisor : -23%, AU$0.10Legend Mining : -22%, AU$0.007Atomos : -20%, AU$0.004White Energy Company : -19%, AU$0.03Paterson Resources : -18%, AU$0.014Avita Medical : -17%, AU$2.47FBR Limited : -17%, AU$0.005Hawthorn Resources : -16%, AU$0.051Middle Island Resources : -14%, AU$0.018","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7090","BK7003","MDR.AU","AVH.AU","BK7095","BK7508","BK7067","BK7077","AMS.AU","PSL.AU","BK7083","LEG.AU","FBR.AU","MDI.AU","BK7094","WEC.AU","HAW.AU","BK7104","SRH.AU"],"gpt_icon":1},{"id":"1178729079","title":"Stock Track | Avita Therapeutics Plummets 20.74% as Q1 Earnings Miss Analyst Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=1178729079","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178729079?lang=en_us&edition=fundamental","pubTime":"2025-05-09 09:08","pubTimestamp":1746752904,"startTime":"0","endTime":"0","summary":"Shares of Avita Therapeutics  plummeted 20.74% in Friday's trading session following the release of its first-quarter earnings report. The sharp decline came as the company's financial results fell short of analyst expectations, despite showing year-over-year improvements.Avita Medical, the parent company of Avita Therapeutics, reported a narrower loss of $0.53 per diluted share for the quarter ended March 31, compared to a loss of $0.73 per share in the same period last year. However, this figu","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Avita Therapeutics Plummets 20.74% as Q1 Earnings Miss Analyst Expectations","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AVH.AU"],"gpt_icon":0},{"id":"2534119703","title":"Avita Medical's Loss Narrows in Q1 as Revenue Grows; Shares Down 20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2534119703","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534119703?lang=en_us&edition=fundamental","pubTime":"2025-05-09 09:05","pubTimestamp":1746752713,"startTime":"0","endTime":"0","summary":"Avita Medical  reported Friday that its first quarter loss narrowed to $0.53 per diluted share from $0.73 per diluted share a year earlier.Analysts polled by Visible Alpha expected a loss of $0.45 per diluted share.Total revenue for the three months ended March 31 was $18.5 million, compared with $11.1 million a year earlier. Analysts surveyed by Visible Alpha expected $20.1 million.The company reaffirmed its full-year 2025 guidance, anticipating commercial revenue of between $100 million and $106 million, indicating a 55% to 65% growth from a year earlier.Shares fell nearly 20% in morning trade Friday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVH.AU"],"gpt_icon":0},{"id":"2529560419","title":"AVITA Medical to Host Acute Wound Care Showcase on May 13, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529560419","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529560419?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:00","pubTimestamp":1745499600,"startTime":"0","endTime":"0","summary":"VALENCIA, Calif., April 24, 2025  -- AVITA Medical, Inc. , a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will host its inaugural Acute Wound Care Showcase 2025 on Tuesday, May 13, 2025, via webcast at 11:00 a.m. Pacific Time.The event will feature presentations from Jim Corbett, Chief Executive Officer, and Dr. Katie Bush, Senior Vice President of Scientific and Medical Affairs. The Acute Wound Care Showcase will provide an overview of AVITA Medical’s comprehensive approach to acute wound care. Attendees joining the webcast will gain insights into the company’s product portfolio, including RECELL, Cohealyx, and PermeaDerm, as well as hear testimonials from physicians and patients.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avita-medical-host-acute-wound-130000752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4139","BK4588","RCEL","BK4585","BK4181","AVH.AU","HST"],"gpt_icon":0},{"id":"2528029773","title":"AVITA Medical to Announce First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2528029773","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528029773?lang=en_us&edition=fundamental","pubTime":"2025-04-18 04:05","pubTimestamp":1744920300,"startTime":"0","endTime":"0","summary":"VALENCIA, Calif., April 17, 2025  -- AVITA Medical, Inc. , a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time  to discuss its financial results and recent business highlights.About AVITA Medical, Inc.AVITA Medical is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL System, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering an innovative solution for improved clinical outcomes at the point-o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avita-medical-announce-first-quarter-200500237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RCEL","BK4139","AVH.AU"],"gpt_icon":0},{"id":"1141929202","title":"Stock Track | Avita Therapeutics Soars 11.20% on Breakthrough Clinical Data Presentation at ABA 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1141929202","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141929202?lang=en_us&edition=fundamental","pubTime":"2025-04-10 08:02","pubTimestamp":1744243368,"startTime":"0","endTime":"0","summary":"Avita Therapeutics  shares are soaring 11.20% in Thursday's trading session, following the announcement of the company's plans to present groundbreaking clinical data at the American Burn Association  2025 Annual Meeting. The significant uptick in share price reflects investors' positive reaction to the company's expanding evidence base and commitment to advancing burn and wound care treatments.Investors appear particularly encouraged by the breadth and depth of the data being presented. Key hig","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Avita Therapeutics Soars 11.20% on Breakthrough Clinical Data Presentation at ABA 2025","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AVH.AU"],"gpt_icon":0},{"id":"2526433613","title":"AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526433613","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526433613?lang=en_us&edition=fundamental","pubTime":"2025-04-10 04:05","pubTimestamp":1744229100,"startTime":"0","endTime":"0","summary":"Sixteen abstracts to present real-world findings and clinical innovations across AVITA Medical’s expanded portfolio, including RECELL, Cohealyx, and PermeaDerm. VALENCIA, Calif., April 09, 2025  -- AVITA Medical, Inc. , a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced 16 abstracts to be presented at the American Burn Association  2025 Annual Meeting, taking place April 8-11 in Phoenix, Arizona. The presentations will feature real-world and clinical data on AVITA Medical’s wound care portfolio, including RECELL, Cohealyx, and PermeaDerm, showcasing the company’s expanded evidence base and commitment to improving outcomes in burn and wound management. Visit AVITA Medical at booth #513 to learn more.Each year, more than 450,000 Americans require medical treatment for burn injuries, often facing prolonged hospitalization, multiple procedures, and complex wound management. AVITA Medical’s technologies are designed to address ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avita-medical-present-breakthrough-clinical-200500697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4139","BK7139","BK7123","BK7508","RCEL","BK7067","ABA.AU","AVH.AU"],"gpt_icon":0},{"id":"2524487472","title":"Avita Medical's Cohealyx Wound Treatment Makes Commercial Launch in US; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524487472","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524487472?lang=en_us&edition=fundamental","pubTime":"2025-04-04 07:36","pubTimestamp":1743723362,"startTime":"0","endTime":"0","summary":"Avita Medical  launched wound care treatment Cohealyx in the US, according to a Friday filing with the Australian bourse.Cohealyx is a collagen-based dermal matrix branded by Avita Medical and co-developed with Regenity Biosciences, the filing stated. It is designed to provide wound bed through cellular migration and revascularization for faster closure.Avita Medical is enrolling participants in the Cohealyx I post-market trial.The company's shares were down almost 4% in recent Friday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVH.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2520516026","title":"Guess which ASX All Ords stock just leapt 9% on big US news","url":"https://stock-news.laohu8.com/highlight/detail?id=2520516026","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520516026?lang=en_us&edition=fundamental","pubTime":"2025-03-18 08:51","pubTimestamp":1742259083,"startTime":"0","endTime":"0","summary":"Commenting on the new agreements helping to lift the ASX All Ords stock today, Avita Medical CEO Jim Corbett said:  These strategic agreements reflect our shared commitment to driving innovation and expanding market access, while ensuring that patients continue to receive first-in-class care. We look forward to leveraging our expertise to continue to drive innovation and growth in therapeutic acute wound care.  Lin Sun, chairman of Stedical Scientific, added:  PermeaDerm has demonstrated great healing results when used for various wounds. We are excited to expand our collaboration with Avita Medical through this manufacturing agreement. This partnership ensures a robust supply chain for PermeaDerm and strengthens our commitment to delivering cutting-edge solutions to the global market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/18/guess-which-asx-all-ords-stock-just-leapt-9-on-big-us-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XAO.AU","BK7508","BK7067","AVH.AU"],"gpt_icon":0},{"id":"2520633277","title":"AVITA Secures Manufacturing, Amends Distribution Agreement with US-Based Healthcare Tech Provider; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2520633277","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520633277?lang=en_us&edition=fundamental","pubTime":"2025-03-18 07:49","pubTimestamp":1742255396,"startTime":"0","endTime":"0","summary":"AVITA Medical  secured a new contract manufacturing agreement and amended its existing distribution agreement for its biosynthetic wound matrix product PermeaDerm, for the treatment of wounds, with Stedical Scientific, according to a Tuesday filing with the Australian bourse.Under the manufacturing agreement, effective Monday, the company will produce PermeaDerm at its Ventura, California facility, while the amended distribution deal revises revenue-sharing terms with Stedical, the filing said.AVITA will retain 60% of sales, with Stedical receiving 40% after manufacturing costs. The agreement also sets performance milestones and extends the contract term, the filing added.Shares of the company rose 7% in recent Tuesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HCSG","BK4137","BK7508","AVH.AU","BK7067"],"gpt_icon":0},{"id":"2519856944","title":"Does Avita Medical (RCEL) Have the Potential to Rally 73.72% as Wall Street Analysts Expect?","url":"https://stock-news.laohu8.com/highlight/detail?id=2519856944","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519856944?lang=en_us&edition=fundamental","pubTime":"2025-03-13 21:55","pubTimestamp":1741874105,"startTime":"0","endTime":"0","summary":"Shares of Avita Medical Inc.  have gained 4.3% over the past four weeks to close the last trading session at $8.98, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.60 indicates a potential upside of 73.7%.The average comprises five short-term price targets ranging from a low of $11 to a high of $21, with a standard deviation of $3.71. While the lowest estimate indicates an increase of 22.5% from the current price level, the most optimistic estimate points to a 133.9% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/does-avita-medical-rcel-potential-135505486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["AVH.AU","BK7067","BK4139","BK7508","RCEL"],"gpt_icon":0},{"id":"2511672246","title":"AVITA Medical Full Year 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2511672246","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511672246?lang=en_us&edition=fundamental","pubTime":"2025-02-15 22:16","pubTimestamp":1739628972,"startTime":"0","endTime":"0","summary":"NasdaqCM:RCEL Earnings and Revenue Growth February 15th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 2.2%. Earnings per share  also missed analyst estimates by 4.1%.Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.The company's shares are up 22% from a week ago.It's still necessary to consider the ever-present spectre of investment risk.   We've identified 1 warning sign  with AVITA Medical, and understanding it should be part of your investment process.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avita-medical-full-2024-earnings-141612158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RCEL","AVH.AU"],"gpt_icon":0},{"id":"2511695448","title":"AVITA Medical to Host Investor Webinar Briefing","url":"https://stock-news.laohu8.com/highlight/detail?id=2511695448","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511695448?lang=en_us&edition=fundamental","pubTime":"2025-02-14 22:15","pubTimestamp":1739542500,"startTime":"0","endTime":"0","summary":"VALENCIA, Calif., Feb. 14, 2025  -- AVITA Medical, Inc. , a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 18, 2025, at 2:00 p.m. Pacific Standard Time .About AVITA Medical, Inc.AVITA Medical is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a groundbreaking solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avita-medical-host-investor-webinar-141500288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4181","BK4139","BK4588","BK4585","RCEL","AVH.AU","HST"],"gpt_icon":0},{"id":"2511682256","title":"Avita Medical Reports Wider Q4 Loss Despite Higher Revenue; Shares Up 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511682256","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511682256?lang=en_us&edition=fundamental","pubTime":"2025-02-14 11:40","pubTimestamp":1739504457,"startTime":"0","endTime":"0","summary":"Avita Medical  reported Friday a loss of $0.44 per diluted share in the fourth quarter of 2024, compared with a loss of $0.28 per diluted share in the same period in 2023.Analysts polled by Visible Alpha also expected a loss of $0.44.The dual-listed firm said the wider net loss was due to higher operating expenses and lower other income, net, partially offset by higher gross profit.Total revenue in the quarter ended Dec. 31, 2024, came in at $18.4 million, compared with $14.2 million in the corresponding period in the prior year. Analysts polled by Visible Alpha expected $20.3 million.The company said it expects its full-year 2025 commercial revenue to be in the range of $100 to $106 million, reflecting growth of approximately 55% to 65% over the full-year 2024.The company's shares surged past 12% in recent Friday trade in Australia.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVH.AU"],"gpt_icon":0},{"id":"2502026876","title":"AVITA Medical, Inc. (RCEL): A Bull Case Theory","url":"https://stock-news.laohu8.com/highlight/detail?id=2502026876","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502026876?lang=en_us&edition=fundamental","pubTime":"2025-01-10 03:04","pubTimestamp":1736449496,"startTime":"0","endTime":"0","summary":"We came across abullish thesison AVITA Medical, Inc.  on Substack by Steve Wagner. In this article, we will summarize the bulls’ thesis on RCEL. AVITA Medical, Inc. 's share was trading at $8.94 as of Jan 8th.A doctor interacting with a patient, discussing the progress of their treatment.Avita Medical  has recently secured FDA approval for its new RECELL GO mini, a disposable cartridge designed specifically for treating smaller wounds up to 480 square centimeters. This innovative product fills a critical gap in the wound care market, particularly for high-volume, smaller wounds typically encountered in trauma and burn centers. Unlike the standard RECELL GO, which is capable of treating wounds up to 1,920 square centimeters, the mini version uses the same multi-use processing device but with an optimized cartridge for smaller skin samples. This adjustment leads to reduced resource consumption and waste, making the product more cost-effective, a key consideration for hospitals facing bud","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avita-medical-inc-rcel-bull-190456504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","MNQmain","TQQQ","USAW.SI","SQQQ","NQmain","TSYW.SI","USJW.SI","QLD","RCEL","BK4139",".IXIC","NVIW.SI","AVH.AU","QID"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVH.AU\",params:#limit:5,,,undefined,":[{"date":"2023-08-10","symbol":"AVH.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1691625600000,"name":null,"time":"","dateTimestamp":1691589600000,"actualEps":null},{"date":"2023-05-11","symbol":"AVH.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1683763200000,"name":null,"time":"","dateTimestamp":1683727200000,"actualEps":null},{"date":"2023-02-23","symbol":"AVH.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1677106800000,"name":null,"time":"","dateTimestamp":1677070800000,"actualEps":null},{"date":"2022-11-10","symbol":"AVH.AU","type":"earning","reportTimeType":"post","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1668034800000,"name":null,"time":"Post Market","dateTimestamp":1667998800000,"actualEps":null},{"date":"2022-08-11","symbol":"AVH.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1660176000000,"name":null,"time":"","dateTimestamp":1660140000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVH.AU\",market:\"AU\",,,undefined,":[]}}